Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.
Dominick Bossé(Dana-Farber Cancer Institute), Toni K. Choueiri(Harvard University), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Sabina Signoretti(Brigham and Women's Hospital), Guru Sonpavde(AdventHealth Orlando), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Wanling Xie(Dana-Farber Cancer Institute), W. Kimryn Rathmell(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), A. Ari Hakimi(Penn State Milton S. Hershey Medical Center), Pheroze Tamboli(The University of Texas MD Anderson Cancer Center), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Guillermo de Velasco(Hospital Universitario 12 De Octubre), Daniel Yick Chin Heng(University of Calgary), Leonard J. Appleman(University of Pittsburgh)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k